

1

2

3 SARS-CoV-2 and endemic coronaviruses: Comparing symptom

4 presentation and severity of symptomatic illness among Nicaraguan

5 Children

6

7 Aaron M Frutos¹, John Kubale¹, Guillermina Kuan², Sergio Ojeda³, Nivea Vydiswaran¹, Nery

8 Sanchez³, Miguel Plazaola³, May Patel¹, Roger Lopez⁴, Angel Balmaseda^{3¶}, Aubree Gordon^{1**¶}

9

10 ¹ Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor,

11 MI, USA

12 ² Health Center Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua

13 ³ Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of

14 Health, Managua, Nicaragua.

15 ⁴ Sustainable Sciences Institute, Managua, Nicaragua.

16

17 *Corresponding author

18 E-mail: gordonal@umich.edu (AG)

19

20 ¶ These authors contributed equally.

21 **Abstract**

22 It has been proposed that as SARS-CoV-2 transitions to endemicity, children will represent the
23 greatest proportion of SARS-CoV-2 infections as they currently do with endemic coronavirus
24 infections. While SARS-CoV-2 infection severity is low for children, it is unclear if SARS-CoV-
25 2 infections are distinct in symptom presentation, duration, and severity from endemic
26 coronavirus infections in children. We compared symptom risk and duration of endemic
27 coronavirus infections from 2011-2016 with SARS-CoV-2 infections from March 2020-
28 September 2021 in a Nicaraguan pediatric cohort. Respiratory samples were collected from
29 participants that met testing criteria and blood samples were collected annually. Respiratory
30 samples were tested for each of the endemic coronaviruses from 2011-2016 and for SARS-CoV-
31 2 from 2020-2021 via rt-PCR. 2021 blood samples were tested for SARS-CoV-2 antibodies and
32 a subset of 2011-2016 blood samples from four-years-old participants were tested for endemic
33 coronavirus antibodies. By April 2021, 854 (49%) active participants were ELISA positive for
34 SARS-CoV-2 antibodies. Most participants had antibodies against one alpha and one beta
35 coronavirus by age four. We observed 595 symptomatic endemic coronavirus infections from
36 2011-2016 and 121 symptomatic with SARS-CoV-2 infections from March 2020-September
37 2021. Symptom presentation of SARS-CoV-2 infection and endemic coronavirus infections
38 were very similar, and SARS-CoV-2 symptomatic infections were as or less severe on average
39 than endemic coronavirus infections. This suggests that, for children, SARS-CoV-2 may be just
40 another endemic coronavirus. However, questions about the impact of variants and the long-term
41 effects of SARS-CoV-2 remain.

42 **Introduction**

43 As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transitions to global
44 endemicity, there are many questions about how that will occur. Over time, children will
45 represent the greatest proportion of primary SARS-CoV-2 infections as adults gain immunity
46 from natural infection or vaccination. (1) It is well established that pediatric risk of severe illness
47 and death is much lower than that for adults. (2, 3) Differences in immune response between
48 adults and children likely provide children better protection against severe SARS-CoV-2
49 infections. (3-5) Previous research found no differences in severity between SARS-CoV-2
50 infections and influenza A and B among children. (6, 7) However, it is unknown if, in children,
51 SARS-CoV-2 infections are distinct in disease presentation and severity from endemic human
52 coronavirus (HCoV) infections. If SARS-COV-2 infections are more severe, routine pediatric
53 vaccination will be necessary to reduce excess mortality. If not, vaccine-induced immunity
54 should prevent severe disease while allow for transmission to facilitate frequent immune
55 boosting. (1) To determine if SARS-CoV-2 infections have distinct disease presentation from
56 endemic HCoV infections in children, we compare symptomatic SARS-CoV-2 and endemic
57 HCoVs infections symptomology and severity in a prospective, community-based pediatric
58 cohort in Managua, Nicaragua from 2011-2016 and 2020-2021

59

60 **Methods**

61 Institutional review boards at the Nicaraguan Ministry of Health and the University of
62 Michigan approved this study. Parents/guardians of participants provided written informed
63 consent and participants aged ≥ 6 years provided verbal assent. The Nicaraguan Pediatric
64 Influenza Cohort Study (NPICS) is a prospective cohort study that began in 2011 and continues
65 today. Participants included in this analysis were members of the NPICS located in District 2 of
66 Managua, Nicaragua between 2011-2016 or March 2020 to September 2021. Children ages 0-14
67 years who live within the catchment area of Health Center Sócrates Flores Vivas were eligible to
68 participate.

69 Blood samples were collected from each study participant between February and April
70 each year. To confirm our assumption that endemic HCoV infection rates are high in the cohort,
71 we tested a random subset of 100 blood samples from four-year-old's from 2011-2016; using
72 protocols for an enzyme-linked immunosorbent assay (ELISA) developed at Mount Sinai (8), we
73 tested samples for antibody response to the spike protein for each of the four endemic HCoV
74 (alpha: NL63, and 229E, beta: OC43 and HKU1). To confirm that SARS-CoV-2 infections rates
75 were also high, we tested the 2021 blood samples for SARS-CoV-2 antibodies as described
76 previously. (9)

77 Parents/guardians agreed to bring participants to the health center at the first signs of
78 fever. Study personnel collected a respiratory swab from participants if they met the testing
79 criteria: feverishness for participants under two years old; measured fever/feverishness and
80 cough, sore throat, or rhinorrhea; severe respiratory symptoms such as apnea or chest indrawing;
81 hospitalization with respiratory symptoms or sepsis. Testing criteria were expanded in June 2020

82 to capture mild symptomatic SARS-CoV-2 cases; however, this analysis is limited to those
83 meeting the original testing criteria to ensure comparability. We used real-time reverse
84 transcription polymerase-chain reaction (RT-PCR) to test respiratory samples from 2011-2016
85 for each of the four endemic HCoV, influenza, respiratory syncytial virus (RSV) and human
86 metapneumovirus (HMPV) and samples from March 2020-September 2021 for SARS-CoV-2
87 and influenza. (10, 11)

88 Study clinicians record all participant symptoms and diagnoses during each clinic visit.
89 Parents/guardians also report participant symptoms at the initial clinic visit, and each day
90 thereafter until symptom resolution. We considered symptoms to be associated with an infection
91 if they occurred within 28 days of symptom onset. Symptoms that were included for follow-up in
92 2011-2016 and 2020-2021 were feverishness, cough, rhinorrhea, nasal congestion, loss of
93 appetite, myalgia, arthralgia, and rapid breathing. We considered participants who presented to
94 the clinic with rapid breathing, rhonchi, indrawing, wheezing, or shortness of breath as having
95 abnormal breathing. We defined acute lower respiratory infections (ALRI) as physician
96 diagnosed cases of pneumonia, bronchiolitis, bronchitis, or bronchial hyperreactivity.

97 To compare risk of symptoms, we calculated symptom specific risk differences between
98 SARS-CoV-2 infections and endemic HCoV infections, overall and stratified by the following
99 age groups: 0-4, 5-9, and 10-14 years. We also stratified the results by sex and endemic HCoV
100 species. Using upset plots, we explored which signs/symptoms tended to present together. We
101 also assessed symptom duration by comparing the time between each specific symptom onset
102 and the last day participants presented with that symptom. We plotted symptom duration using

103 boxplots and compared the distribution of symptom duration between SARS-CoV-2 and
104 endemic HCoV using the Mann Whitney U test.

105 We used SAS version 9.4 (SAS Institute Inc.) to calculate risk differences and ratios and
106 R version 4.1.0 to create figures and conduct all other analyses.

107

108 **Results**

109 There were 3,220 participants active in NPICS during the included years: 2,576 from
110 2011-2016 and 1,942 from March 2020-September 2021 with an average of 1,792 per year. Our
111 assumption that detected symptomatic infections consist of only a small proportion of total
112 SARS-CoV-2 and endemic HCoV infections that occurred in the cohort children. Specifically, of
113 the 1,942 children in the cohort from March 2020-September 2021, 1,743 had a blood sample
114 collected in early to mid- 2021 that was tested via ELISA for SARS-CoV-2. 854 (49%) tested
115 positive for SARS-CoV-2 antibodies indicating that SARS-CoV-2 infections were very high in
116 the cohort. We found that 94% of our randomly selected subset of four-year-olds from 2011-
117 2016 had an antibody response to at least one alpha and one beta HCoV, confirming our
118 assumption of high endemic HCoV infection rates in the community. Antibody response
119 prevalence was highest for OC43 (99%) followed by HKU1 (86%), NL63 (83%), and then 229E
120 (74%) (Table 1).

121

122 **Table 1: Endemic Coronavirus ELISA Results, % Positive**

| Total (n=100) | |
|----------------------|------|
| Alpha | 94% |
| NL63 | 83% |
| 229E | 74% |
| Beta | 100% |
| OC43 | 99% |
| HKU1 | 86% |

123

124

125

126

127

128

129

130

131

132

133

134

Within this cohort we observed high infection rates of both endemic HCoV-229E and SARS-CoV-2. That there were 595 RT-PCR+ symptomatic endemic HCoV infections from 2011-2016 and 121 RT-PCR+ symptomatic SARS-CoV-2 infections from March 2020- September 2021 again suggests that symptomatic cases represent only a small proportion of overall infections. Most endemic HCoV, 432 (73%), and SARS-CoV-2, 59 (49%), infections occurred in participants <5 years. Fever, cough, rhinorrhea, and congestion were the most common symptoms for both endemic HCoVs and SARS-CoV-2 symptomatic infections. Among SARS-CoV-2 symptomatic infections, 4 (3%) were acute lower respiratory infections compared to 98 (16%) endemic HCoV cases (p=<0.0001; Table 2).

Table 2: Study Participants and Symptom Prevalence

| | Endemic (n=595) | SARS-CoV-2 (n=121) | p-value |
|----------------------|----------------------------|-------------------------------|----------------|
| Age Group (%) | | | <.0001 |
| 0-4 | 432 (73) | 59 (49) | |
| 5-9 | 110 (18) | 29 (24) | |
| 10-14 | 53 (9) | 33 (27) | |
| Symptoms (%) | | | |
| Measured Fever | 272 (46) | 68 (56) | 0.035 |
| Cough | 524 (88) | 85 (70) | <0.001 |

| | | | |
|-----------------------------------|----------|---------|--------|
| Rhinorrhea | 505 (85) | 93 (77) | 0.030 |
| Congestion | 276 (46) | 45 (37) | 0.064 |
| Sore Throat | 145 (24) | 36 (30) | 0.221 |
| Headache | 81 (14) | 38 (31) | <0.001 |
| Loss of Appetite | 142 (24) | 30 (25) | 0.828 |
| Diarrhea | 64 (11) | 14 (12) | 0.793 |
| Pneumonia | 40 (7) | 4 (3) | 0.154 |
| Hospitalized | 23 (4) | 6 (5) | 0.578 |
| Abnormal Breathing | 108 (18) | 8 (6) | 0.002 |
| Acute Lower Respiratory Infection | 98 (16) | 4 (3) | <0.001 |

135

136 * p-value from chi-square test

137

138 Across age groups, participants with symptomatic endemic HCoV infections displayed

139 greater risk of cough compared to those with symptomatic SARS-CoV-2 infections. Among

140 participants aged <5 years, symptomatic endemic HCoV infections showed greater risk of

141 rhinorrhea, congestion, abnormal breathing, and ALRI than symptomatic SARS-CoV-2

142 infections, while SARS-CoV-2 exhibited greater risk of measured fever (Fig 1, Table 3).

143 Notably, symptomatic endemic HCoV infection was associated with greater risk of ALRI even

144 after excluding participants that also tested positive for influenza A, influenza B, RSV, or

145 HMPV. We observed no difference in risk of pneumonia or hospitalization between SARS-CoV-

146 2 and endemic HCoV symptomatic infections. These results were consistent after stratifying by


147 sex (S1-S2 Fig), or endemic HCoV species (S3-S6 Fig).

148

149

150 **Fig 1: Symptom Risk Difference between Endemic HCoV and SARS-CoV-2.**

151



152

153 A: All participants. B: Ages 0-4 years. C: Ages 5-9 years. D Ages: 10-14 years. Positive risk

154 difference indicates higher risk for endemic HCoVs.

155 **Table 3: Symptom Risk Overall and by Age Group**

| All | | | | |
|---------------------------|-------------|----------------|--------------------------|---------------------|
| | Endemic (%) | SARS-CoV-2 (%) | Risk Difference (95% CI) | Risk Ratio (95% CI) |
| Measured Fever | 272 (46) | 68 (56) | -0.10 (-0.20, -0.01) | 0.81 (0.68, 0.97) |
| Cough | 524 (88) | 85 (70) | 0.18 (0.09, 0.26) | 1.25 (1.11, 1.41) |
| Runny nose | 505 (85) | 93 (77) | 0.08 (-0.00, 0.16) | 1.10 (1.00, 1.22) |
| Congestion | 276 (46) | 45 (37) | 0.09 (-0.00, 0.19) | 1.24 (0.97, 1.60) |
| Sore throat | 145 (24) | 36 (30) | -0.05 (-0.14, 0.03) | 0.82 (0.60, 1.11) |
| Headache | 81 (14) | 38 (31) | -0.18 (-0.27, -0.09) | 0.43 (0.31, 0.60) |
| Loss of appetite | 142 (24) | 30 (25) | -0.01 (-0.09, 0.07) | 0.96 (0.68, 1.35) |
| Diarrhea | 64 (11) | 14 (12) | -0.01 (-0.07, 0.05) | 0.93 (0.54, 1.60) |
| Pneumonia | 40 (7) | 4 (3) | 0.03 (-0.00, 0.07) | 2.03 (0.74, 5.58) |
| Hospitalized | 23 (4) | 6 (5) | -0.01 (-0.05, 0.03) | 0.78 (0.32, 1.87) |
| Abnormal Breathing | 108 (18) | 8 (7) | 0.12 (0.06, 0.17) | 2.75 (1.38, 5.48) |
| ALRI | 98 (16) | 4 (3) | 0.13 (0.09, 0.18) | 4.98 (1.87, 13.28) |
| ALRI[†] | 77 (15) | 4 (3) | 0.12 (0.07,0.16) | 4.55 (1.70, 12.19) |
| 0-4 | | | | |
| | Endemic (%) | SARS-CoV-2 (%) | Risk Difference (95% CI) | Risk Ratio (95% CI) |
| Measured Fever | 218 (50) | 44 (75) | -0.24 (-0.36, -0.12) | 0.68 (0.57, 0.81) |
| Cough | 382 (88) | 42 (71) | 0.17 (0.05, 0.29) | 1.24 (1.05, 1.47) |
| Runny nose | 378 (88) | 42 (71) | 0.16 (0.04, 0.28) | 1.23 (1.04, 1.45) |
| Congestion | 241 (50) | 21 (36) | 0.14 (0.09, 0.27) | 1.39 (0.97, 1.99) |
| Sore throat | 66 (15) | 6 (10) | 0.05 (-0.03, 0.14) | 1.50 (0.68, 3.31) |
| Headache | 23 (5) | 4 (7) | -0.01 (-0.08, 0.05) | 0.79 (0.28, 2.19) |
| Loss of appetite | 116 (27) | 18 (31) | -0.04 (-0.16, 0.09) | 0.88 (0.58, 1.33) |
| Diarrhea | 58 (13) | 9 (15) | -0.02 (-0.12, 0.08) | 0.88 (0.46, 1.68) |
| Pneumonia | 38 (9) | 3 (5) | 0.04 (-0.03, 0.10) | 1.73 (0.54, 6.03) |
| Hospitalized | 17 (4) | 4 (7) | -0.03 (-0.10, 0.04) | 0.58 (0.20, 1.67) |
| Abnormal Breathing | 95 (22) | 3 (5) | 0.17 (0.10, 0.24) | 4.34 (1.42, 13.21) |
| ALRI | 88 (20) | 3 (5) | 0.15 (0.9, 0.22) | 4.00 (1.31, 12.26) |
| ALRI[†] | 69 (19) | 3 (5) | 0.13 (0.07,0.20) | 3.65 (1.19, 11.21) |
| 5-9 | | | | |
| | Endemic (%) | SARS-CoV-2 (%) | Risk Difference (95% CI) | Risk Ratio (95% CI) |
| Measured Fever | 39 (35) | 12 (41) | -0.06 (-0.26, 0.14) | 0.86 (0.52, 1.41) |
| Cough | 99 (90) | 21 (72) | 0.18 (0.00, 0.35) | 1.24 (0.98, 1.57) |
| Runny nose | 87 (79) | 25 (86) | -0.07 (-0.22, 0.08) | 0.92 (0.77, 1.09) |

| | | | | |
|---------------------------|---------|---------|---------------------|--------------------|
| Congestion | 42 (38) | 14 (48) | -0.10 (-0.10, 0.30) | 0.79 (0.51, 1.23) |
| Sore throat | 52 (47) | 12 (41) | 0.06 (-0.14, 0.26) | 1.14 (0.71, 1.84) |
| Headache | 35 (32) | 14 (48) | -0.16 (-0.37, 0.04) | 0.66 (0.41, 1.04) |
| Loss of appetite | 19 (17) | 7 (24) | -0.07 (-0.24, 0.10) | 0.72 (0.33, 1.54) |
| Diarrhea | 4 (4) | 3 (10) | -0.07 (-0.18, 0.05) | 0.35 (0.08, 1.48) |
| Pneumonia | 2 (2) | 1 (3) | -0.02 (-0.9, 0.05) | 0.53 (0.05, 5.61) |
| Hospitalized | 5 (5) | 2 (7) | -0.02 (-0.12, 0.08) | 0.66 (0.13, 3.23) |
| Abnormal Breathing | 10 (9) | 2 (7) | 0.02 (-0.08, 0.12) | 1.32 (0.31, 5.69) |
| ALRI | 8 (7) | 1 (3) | 0.04 (-0.04, 0.12) | 2.11 (0.27, 16.19) |
| ALRI[†] | 6 (7) | 1 (3) | 0.03 (-0.05, 0.11) | 1.89 (0.23, 16.93) |

10-14

| | Endemic (%) | SARS-CoV-2 (%) | Risk Difference (95% CI) | Risk Ratio (95% CI) |
|---------------------------|-------------|----------------|--------------------------|---------------------|
| Measured Fever | 15 (28) | 12 (36) | -0.08 (-0.28, 0.12) | 0.78 (0.42, 1.45) |
| Cough | 43 (81) | 22 (67) | 0.14 (-0.05, 0.34) | 1.22 (0.93, 1.60) |
| Runny nose | 40 (75) | 26 (79) | -0.03 (-0.21, 0.15) | 0.96 (0.76, 1.21) |
| Congestion | 20 (38) | 10 (30) | 0.07 (-0.13, 0.28) | 1.25 (0.67, 2.32) |
| Sore throat | 27 (51) | 18 (55) | -0.04 (-0.25, 0.18) | 0.93 (0.62, 1.41) |
| Headache | 23 (43) | 20 (61) | -0.17 (-0.39, 0.04) | 0.25 (0.47, 1.08) |
| Loss of appetite | 7 (13) | 5 (15) | -0.02 (-0.17, 0.13) | 0.87 (0.30, 2.52) |
| Diarrhea | 2 (4) | 2 (6) | -0.02 (-0.12, 0.07) | 0.62 (0.09, 4.21) |
| Pneumonia | 0 | 0 | - | - |
| Hospitalized | 1 (2) | 0 | 0.02 (-0.02, 0.06) | - |
| Abnormal Breathing | 3 (6) | 3 (9) | -0.03 (-0.15, 0.08) | 0.62 (0.13, 2.90) |
| ALRI | 2 (4) | 0 | 0.04 (-0.01, 0.09) | - |
| ALRI[†] | 2 (4) | 0 | 0.04 (-0.01, 0.10) | - |

156 *Positive risk difference, risk ratio > 1 indicates higher risk for endemic HCoV infection.

157 † Excluding influenza A, influenza B, RSV, and HmpV coinfections

158

159 For both endemic HCoV and SARS-CoV-2, we found that cough, rhinorrhea, and sore
 160 throat frequently presented together. Loss of appetite appeared in common symptom groupings
 161 for endemic HCoV, while headache was part of more common groupings for SARS-CoV-2 (Fig
 162 2). We did find that among participants aged 0-4 years decreased appetite lasted longer and


163 among participants aged 5-9 and 10-14, cough lasted longer for SARS-CoV-2 infections., (Fig 2,
164 Supplemental Table 4).

165


166 **Fig 2. Comparison of Common Symptom Groupings and Duration between Symptomatic**

167 **Endemic Coronavirus and SARS-CoV-2 Infections.**


A



B



C



169 A: Upset plot of symptom groupings for symptomatic SARS-CoV-2 infections. B. Upset plot of
 170 symptom groupings for symptomatic endemic coronavirus infections. C. Boxplots of symptom
 171 duration

172

173 **Table 4: Symptom Duration Comparison: SARS-CoV-2, Endemic Coronaviruses**

| Mean Symptom Duration in Days (SD) | | | |
|---|-------------------|------------------------------|-----------------|
| | All | | p-value* |
| | SARS-CoV-2 | Endemic Coronaviruses | |
| Feverish | 3.8 (6.1) | 3.8 (7.1) | 0.137 |
| Cough | 6.7 (6.4) | 5.5 (8.0) | 0.003 |
| Runny nose | 4.4 (5.7) | 4.6 (7.3) | 0.354 |
| Congestion | 2.8 (4.7) | 2.8 (5.6) | 0.997 |
| Decreased appetite | 2.2 (2.8) | 1.4 (3.4) | 0.032 |
| 0-4 | | | |
| | SARS-CoV-2 | Endemic Coronaviruses | p-value* |
| Feverish | 5.2 (7.3) | 4.4 (7.6) | 0.069 |
| Cough | 6.4 (6.0) | 6.4 (8.6) | 0.178 |
| Runny nose | 5.1 (5.8) | 5.4 (7.8) | 0.278 |
| Congestion | 2.6 (3.8) | 3.0 (5.8) | 0.875 |
| Decreased appetite | 2.5 (2.9) | 1.6 (3.7) | 0.039 |
| 5-9 | | | |
| | SARS-CoV-2 | Endemic Coronaviruses | p-value* |
| Feverish | 2.0 (4.0) | 2.4 (5.4) | 0.397 |
| Cough | 8.1 (7.5) | 3.2 (5.8) | 0.002 |
| Runny nose | 3.9 (5.5) | 2.3 (4.7) | 0.125 |
| Congestion | 3.4 (6.3) | 1.9 (4.4) | 0.690 |
| Decreased appetite | 2.1 (2.6) | 1.0 (1.2) | 0.351 |
| 10-14 | | | |
| | SARS-CoV-2 | Endemic Coronaviruses | p-value* |
| Feverish | 2.6 (4.7) | 1.7 (3.8) | 0.434 |
| Cough | 6.0 (6.2) | 2.3 (4.3) | 0.015 |
| Runny nose | 3.5 (6.0) | 2.2 (5.0) | 0.440 |
| Congestion | 2.5 (3.9) | 2.6 (5.6) | 0.479 |
| Decreased appetite | 1.2 (2.2) | 0.4 (0.8) | 0.698 |

*From Mann-Whitney U test

174

175

176

177

178

179

180

181


182

183


To assess the potential impact of variants on symptoms, we compared symptoms for SARS-CoV-2 infections from 2020 prior to the global emergence of variants and 2021 when delta, gamma, and lambda strains circulated in the cohort area and found no difference in presentation by year (Fig 3). All observed cases of ALRI associated with SARS-CoV-2 occurred in 2020. However, we did find that rhinorrhea lasted longer in SARS-CoV-2 cases from 2021 compared to 2020 (Table 5).

Fig 3. Comparison of Common Symptom Groupings between Symptomatic SARS-CoV-2 Infections in 2020 and 2021

A



B



185 A: 2020. B. 2021

186

187 **Table 5: Symptom Duration Comparison: SARS-CoV-2 by Year**

| | Mean Symptom Duration in Days (SD) | | p-value* |
|--------------------|---|-------------|-----------------|
| | 2020 | 2021 | |
| Feverish | 4.1 (7.4) | 3.46(5.0) | 0.129 |
| Cough | 6.8 (8.0) | 6.7 (5.5) | 0.378 |
| Runny nose | 2.7 (5.0) | 5.4 (6.0) | 0.004 |
| Congestion | 1.6 (2.3) | 3.3 (5.2) | 0.382 |
| Decreased appetite | 3.5 (3.8) | 1.6 (1.9) | 0.172 |

*From Mann-Whitney U test

188

189 **Discussion**

190 This is, to our knowledge, the first study that assesses differences in symptom
191 presentation, duration, and severity between SARS-CoV-2 and endemic HCoV symptomatic
192 infections among children. Understanding how SARS-CoV-2 infections compare to endemic
193 HCoV infections is important as SARS-CoV-2 becomes endemic. While our study does not
194 evaluate asymptomatic or very mild illness, we provide comparisons of medically attended
195 illness associated with endemic HCoV and SARS-CoV-2 symptomatic infections in a large
196 cohort of children with high infection rates.

197 In this pediatric cohort, we found that with 854 (49%) participants tested positive for
198 SARS-CoV-2 antibodies in 2021 with only 121 PCR confirmed infections that met the original
199 testing criteria, like results from our community-based household cohort study. (9) We also
200 found that most participants had at least one alpha and one beta HCoV infection by age four

201 suggesting that in this cohort, participants have had at least two endemic HCoV exposures by the
202 age of four. This is similar to previous studies that showed that by age six, most children have
203 had infections with each of the four endemic HCoVs with a majority being asymptomatic
204 infections. (12) Thus for SARS-CoV-2 and endemic HCoV, symptomatic infections also
205 represent only a small proportion of all pediatric infections.

206 Comparing these symptomatic infections, we found that, overall, disease presentation is
207 very similar between endemic HCoV and SARS-CoV-2, with each frequently presenting with
208 “common cold” symptoms. Consistent with other studies, we found differences in symptom
209 presentation by age perhaps in part because older children have had more endemic HCoV
210 exposures (2, 4, 13). We also found great variability in symptom duration for SARS-CoV-2 and
211 endemic HCoV infections with symptoms lasting from 1-28 days or more. (14) There was a
212 difference in duration of decreased appetite for the youngest participants and cough for those
213 aged 5-14 years suggesting that some symptoms may last longer for SARS-CoV-2 infections.
214 We also found a difference in rhinorrhea duration between SARS-CoV-2 infections in 2020 and
215 2021, suggesting that SARS-CoV-2 variants may increase symptom duration among children.

216 Across age groups, risk of ALRI associated with SARS-CoV-2 was the same or lower
217 compared to ALRI associated with endemic HCoV infection. Even when excluding endemic
218 HCoV co-infections with pathogens commonly associated with ALRI, the conclusions did not
219 change. These results show that, for children, the risk of ALRI and severe illness from SARS-
220 CoV-2 infections is comparable to the risk from endemic HCoV infections at the community
221 level.

222 The main strength of this community-based study is its size and duration. Consistent viral
223 surveillance and symptom evaluation within the same population allow for year-to-year
224 comparisons and facilitates our comparisons of endemic HCoV and SARS-CoV-2. The high
225 number of participants under the age of five (about 36% of participants during these years),
226 allows us to evaluate SARS-CoV-2 in an age group with little representation in current literature.
227 Additionally, this cohort was already well established when SARS-CoV-2 began circulating in
228 Nicaragua allowing us to quickly incorporate questions regarding its effects on this population.

229 However, this study does have some limitations. First, using data from this community-
230 based cohort study we were not powered to detect the most severe manifestations of SARS-CoV-
231 2 including death or Multisystem Inflammatory Syndrome in Children (MIS-C) and other rare
232 outcomes. (15, 16) Second, our analysis did not include genetic sequencing preventing us from
233 assessing the importance of variants in presentation and severity of SARS-CoV-2 illness. We did
234 compare SARS-CoV-2 symptom presentation, severity, and duration by year and found little or
235 no difference. Finally, while our study does not evaluate asymptomatic illness for endemic
236 HCoVs, our results were consistent with other research, showing that childhood HCoVs are
237 ubiquitous and that symptomatic cases represent only a small proportion of infections, as with
238 SARS-CoV-2. (12)

239 In this study, we observed that symptomatic SARS-CoV-2 infections at the community
240 level are very similar to symptomatic endemic HCoV infections in symptom presentation.
241 Among children in a setting with a high SARS-CoV-2 infection rate, symptomatic SARS-CoV-2
242 infections are on average as or less severe as endemic HCoV infections. These findings support

243 the hypothesis that SARS-CoV-2 may be like another endemic HCoV for children—most
244 children will be asymptomatic with rare cases of severe symptomatic illness. This does not mean
245 SARS-CoV-2 in children is not important. There are many unknowns about the long-term effects
246 and impact of repeat infections among children. (1) Increased transmissibility of emerging
247 variants is also a cause for concern, as it will lead to increased frequency of severe
248 manifestations. Future mutations in the virus needed to be monitored as they may also increase
249 illness severity in children. Despite relatively low risk of severe illness among children, pediatric
250 vaccination that mirrors natural induced immunity against SARS-CoV-2 would further lower
251 individual risk and reduce the number of severe cases and deaths due to SARS-CoV-2.

252

253 **References**

- 254 1. Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of
255 COVID-19 to endemicity. *Science*. 2021;371(6530):741-5.
- 256 2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among
257 Children in China. *Pediatrics*. 2020;145(6).
- 258 3. Do LAH, Anderson J, Mulholland EK, Licciardi PV. Can data from paediatric cohorts
259 solve the COVID-19 puzzle? *PLoS Pathog*. 2020;16(9):e1008798.
- 260 4. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why
261 Children Fare Better than Adults? *Indian J Pediatr*. 2020;87(7):537-46.
- 262 5. Khan T, Rahman M, Ali FA, Huang SSY, Ata M, Zhang Q, et al. Distinct antibody
263 repertoires against endemic human coronaviruses in children and adults. *JCI Insight*. 2021;6(4).

- 264 6. Siddiqui M, Gultekingil A, Bakirci O, Uslu N, Baskin E. Comparison of clinical features
265 and laboratory findings of coronavirus disease 2019 and influenza A and B infections in
266 children: a single-center study. *Clin Exp Pediatr*. 2021.
- 267 7. Pokorska-Spiewak M, Talarek E, Popielska J, Nowicka K, Oldakowska A, Zawadka K, et
268 al. Comparison of clinical severity and epidemiological spectrum between coronavirus disease
269 2019 and influenza in children. *Sci Rep*. 2021;11(1):5760.
- 270 8. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al.
271 SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen
272 Production, and Test Setup. *Curr Protoc Microbiol*. 2020;57(1):e100.
- 273 9. Maier HE, Kuan G, Saborio S, Bustos Carrillo FA, Plazaola M, Barilla C, et al. Clinical
274 spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection. *Clin Infect*
275 *Dis*. 2021.
- 276 10. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular Diagnosis
277 of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin Chem*.
278 2020;66(4):549-55.
- 279 11. Real-Time RT-PCR Assays for Non-Influenza Respiratory Viruses. In: *Diseases NCfIaR*,
280 editor.: Centers for Disease Control and Prevention; 2015. p. 1-16.
- 281 12. Zhou W, Wang W, Wang H, Lu R, Tan W. First infection by all four non-severe acute
282 respiratory syndrome human coronaviruses takes place during childhood. *BMC Infect Dis*.
283 2013;13:433.

- 284 13. Ogimi C, Kim YJ, Martin ET, Huh HJ, Chiu CH, Englund JA. What's New With the Old
285 Coronaviruses? J Pediatric Infect Dis Soc. 2020;9(2):210-7.
- 286 14. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al. Illness
287 duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2.
288 Lancet Child Adolesc Health. 2021.
- 289 15. Children and COVID-19: State-Level Data Report. American Academy of Pediatrics
290 2021 August 12, 2021.
- 291 16. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al.
292 Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected
293 With SARS-CoV-2. JAMA Netw Open. 2021;4(6):e2116420.

294

295 **Supporting information**

296

297


298

299

300

301

302 **S1 Fig. Symptom Risk Difference between Endemic HCoV and SARS-CoV-2 for Females.**




303

304 A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates

305 higher risk for endemic HCoV infection

306

307 **S2 Fig. Symptom Risk Difference between Endemic HCoV and SARS-CoV-2 for Males.**




308

309 A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates

310 higher risk for endemic HCoV infection

311

312 **S3 Fig. Symptom Risk Difference NL63 and SARS-CoV-2.**




313

314 A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates

315 higher risk for endemic HCoV infection

316

317 **S4 Fig. Symptom Risk Difference between 229E and SARS-CoV-2.**




318

319 A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates

320 higher risk for endemic HCoV infection

321

322 **S5 Fig. Symptom Risk Difference between OC43 and SARS-CoV-2.**




323

324 A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates

325 higher risk for endemic HCoV infection

326

327 **S6 Fig. Symptom Risk Difference between HKU1 and SARS-CoV-2.**



328

329 A: All participants. B: Ages 0-4. C: Ages 5-9. D Ages: 10-14. Positive risk difference indicates

330 higher risk for endemic HCoV infection